|Day Low/High||56.03 / 57.17|
|52 Wk Low/High||21.98 / 82.49|
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All Patients Through up to 3.
A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.
Here's what you need to know for Monday, April 9.
Data Demonstrate Clinical Effectiveness and Superior Immunogenicity Profile of AAV5 Gene Therapy in Severe and Moderate-Severe Hemophilia B Patients
Here are how some of the conference presenters are performing on the market Wednesday
~ New Nonclinical Data on AMT-061 to be Presented Saturday, December 9, 2017 ~
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.